ALTIMMUNE
Altimmune is an emerging biotechnology company located in Montgomery County, MD. Altimmune develops vaccines and other biological products to address unmet market and public health needs. The company uses a proprietary technology for non-invasive intranasal delivery, and has shown proof of principle in animals and in initial human clinical studies. Vaxin Inc., formerly known as Vaxin Pharmaceuticals and ImmuneFocus Corporation, was founded in 1997 by Emerging Technology Partners. Early experiments revealed that DNA incorporated into an adenovirus can elicit an immune response when placed on the surface of the skin, and subsequently research was expanded to include applications on the skin in the nose as well as experimentation with other vectors.
ALTIMMUNE
Industry:
Biotechnology Clinical Trials Health Care Test And Measurement
Founded:
1997-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.altimmune.com
Total Employee:
11+
Status:
Active
Contact:
8555571369
Email Addresses:
[email protected]
Total Funding:
51.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-07-09 | Spitfire Pharma | Spitfire Pharma acquired by Altimmune | 93 M USD |
| 2017-01-19 | PharmAthene | PharmAthene acquired by Altimmune | N/A |
| 2015-02-17 | Immune Targeting Systems | Immune Targeting Systems acquired by Altimmune | N/A |
Investors List
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - Altimmune
HealthCap
HealthCap investment in Post-IPO Equity - Altimmune
Novartis Venture Fund
Novartis Venture Fund investment in Post-IPO Equity - Altimmune
Redmont Capital
Redmont Capital investment in Post-IPO Equity - Altimmune
Truffle Capital
Truffle Capital investment in Post-IPO Equity - Altimmune
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-13 | Altimmune Appoints Richard Eisenstadt as Chief Financial Officer |
Official Site Inspections
http://www.altimmune.com Semrush global rank: 4.94 M Semrush visits lastest month: 1.73 K
- Host name: cloudproxy10064.sucuri.net
- IP address: 192.124.249.64
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Altimmune"
Altimmune a clinical stage biopharmaceutical company
910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450See details»
ABOUT US | Altimmune Website
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the …See details»
Altimmune, Inc. - LinkedIn
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product...See details»
Altimmune, Inc. - AnnualReports.com
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver …See details»
Altimmune open to partnerships, deals with drugmakers, says CEO
Dec 5, 2023 · Weight-loss drug developer Altimmune is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its experimental …See details»
Altimmune - The Org
Altimmune is a clinical stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment …See details»
Altimmune, Inc. (ALT) Company Profile & Overview - Stock Analysis
6 days ago · Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, …See details»
Press Releases - Altimmune
GAITHERSBURG, Md. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter …See details»
Altimmune Announces Third Quarter 2024 Financial Results and …
GAITHERSBURG, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the third …See details»
Altimmune Announces Positive Interim Data from ALT-801 Phase …
GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6 …See details»
Altimmune Commences Enrollment in Phase 1 Clinical …
GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced enrollment in a Phase 1 clinical trial of AdCOVID, a …See details»
Clinical Trials | Altimmune Website
Topline data in Q2 2025.See details»
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
Dec 4, 2023 · Altimmune, Inc. ALT, a clinical-stage company, announced positive top-line results from the 48-week phase II MOMENTUM study of its obesity drug candidate, pemvidutide.See details»
Altimmune Presents Data from Phase 2 MOMENTUM Trial of
Jun 23, 2024 · Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing …See details»
Altimmune, Inc. (ALT) Interactive Stock Chart - Yahoo Finance
Interactive Chart for Altimmune, Inc. (ALT), analyze all the data with a huge range of indicators.See details»
Altimmune: Pemvidutide Data Reinforces Obesity Drug Outlook
Dec 6, 2023 · Altimmune has made a good amount of progress in being able to advance pemvidutide for the treatment of patients with obesity and NASH. Find out why ALT stock is a …See details»
Altimmune to Present at Upcoming Conferences
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the …See details»
Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Seeking …
Jun 24, 2024 · Shares of Altimmune, Inc. (NASDAQ: ALT), the Gaithersburg, Maryland-based biotech focused on development of its GLP-1/glucagon dual receptor agonist, pemvidutide, in …See details»
Altimmune: Despite HepTcell Failure, Differentiation Of Obesity …
Mar 27, 2024 · Read about the positive outcomes of Altimmune's PEMVIDUTIDE phase 2 MOMENTUM study and its potential impact on the GLP-1 market. Explore my ALT stock …See details»
Altimmune reports positive results for its obesity drug - MedWatch
Dec 1, 2023 · Altimmune reports positive results for its obesity drug In a 48-week trial, the highest dose of the drug helped patients lose up to 16% of their body weight.See details»